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Bioprospecting of actinobacteria from understudied ecosystems is a promising source for extracting novel bioactive 
metabolites. A study was undertaken to characterize and analyze the bio-efficacy of actinobacterial extract for antimicrobial, 
larvicidal, and antioxidant activities. Seven morphologically different actinobacterial cultures isolated from mangrove 
rhizosphere sediment near Parangipettai, South India, were tested for antimicrobial activity. Bioactive metabolites from one 
potential strain PA9 were produced by submerged fermentation. The selected Streptomyces sp. PA9 was subjected to the 
production of crude extract for antimicrobial, larvicidal, and antioxidant activity. The actinobacterial compound was 
characterized by Fourier transform infrared spectroscopy (FTIR), high-performance liquid chromatography (HPLC), and gas 
chromatography–mass spectrometry (GC–MS). The PA9 actinobacterial crude extract showed best antimicrobial activity 
against clinical bacteria, Salmonella typhi (21.6 ± 0.88 mm) and fungi, Candida albicans (26.6 ± 0.88 mm). The PA9 extract 
showed significant larvicidal activity against Culex quinquefasciatus with LC50=173.21 µg/ml and r2=0.841. The PA9 
extract also exhibited antioxidant activity from DPPH (72%) and nitric oxide free radicals (85%). The characterization of the 
PA9 extract by FTIR analysis showed the presence of possible functional groups. Active compounds were isolated by HPLC 
and GC–MS with major and minor peaks observed on the basis of retention time. The bio-efficacy of PA9 has warranted 
further studies to develop a baseline for the drug development. 
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Introduction 
In the last 20 years, more than 30 new diseases 
have emerged, which together threaten the health of 
hundreds of millions of people. Some of the major 
diseases such as cholera, malaria, and tuberculosis are 
making a deadly comeback in many parts of the 
world, despite being preventable or treatable1. 
Meanwhile, antibiotics used against many diseases are 
rapidly losing their efficiency because of resistance by 
microbes. Thus, the quest for better antibiotics is an 
unceasing process in the medical world2.  
Biologically active metabolites are produced by some 
organisms, such as bacteria, fungi, plants, and 
actinobacteria. Among the different groups of organisms 
that have the ability to produce such metabolites,  
the actinobacteria occupy a prominent place3. 
Actinobacteria are a diverse group of filamentous Gram-
positive and aerobic bacteria having high G+C content 
(more than 50%) and they play a major role in the 
medical field; they are producers of biologically active 
secondary metabolites, such as antibiotics, enzymes, and 
vitamins4,5. About 70% of naturally occurring bioactive 
compounds have been separated from different genera of 
actinobacteria6. Streptomyces is the largest genus known 
for the production of many secondary metabolites7, 
which have various biological activities, such as 
antibacterial, antifungal, antiparasitic, antitumor, 
anticancer, and immunosuppressive actions8,9. 
It is well known that actinobacteria are potential 
sources of antibiotics, which could profitably be 
developed in the pharmaceutical industries and the best-
known example is the products of Streptomyces. There 
is an increasing demand for new types of antibiotics to 
control mosquitoes and infectious diseases. With this 
perspective, the present study is aimed at producing 
potential secondary metabolites from actinobacteria for 
various biomedical applications.  
 
Materials and Methods 
Preparation of medium for culture  
The actinobacterial strains used in this study were 
isolated from marine sediment samples collected from 
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mangrove rhizosphere region, Parangipettai  
(Lat: 11.5085°N; Long: 79.7568°E), Tamil Nadu, 
India, by the standard spread plate method using 
starch casein nitrate agar. The cultures were revived 
in yeast extract malt extract (YEME) agar (g/L: yeast 
extract 4; malt extract 10; glucose 4; NaCl 5; Agar 18; 
pH 7±0.2) medium.  
 
Preliminary screening for antimicrobial activity 
Morphologically different actinobacterial strains 
were selected and screened for antimicrobial activity 
by the agar plug method. All the actinobacterial 
strains were grown on YEME agar plates (20 ml/plate) 
and incubated at 28 °C for 7 to10 days. After 
removing the mycelia growth, an agar plug of 5 mm 
diameter was cut from the YEME agar plates. The test 
organisms were inoculated in Muller Hinton Agar 
(MHA) plates using a sterile cotton swab. The agar 
plugs were placed over the MHA with test bacterial 
strains, such as Staphylococcus aureus, Escherichia 
coli, and Klebsiella pneumoniae. The zone of 
inhibition was measured after 24 h of incubation at 37 °C 
and its diameter expressed in millimeters10. 
 
Production and extraction of bioactive metabolites 
Bioactive metabolites from the selected strains 
PA6, PA9, PA12, and PA13 were produced by agar 
surface fermentation using YEME agar11. After five 
days of incubation at 28 °C, the metabolite produced 
by the strains in the agar medium was extracted using 
ethyl acetate as organic solvent. The solvent extracts 
were collected and concentrated using a rotary 
vacuum evaporator. Further, the crude extracts were 
tested against a group of bacterial and fungal 
pathogens.  
 
Antimicrobial activity 
The solvent extracts were tested for antibacterial 
and antifungal activities using bacterial pathogens, 
namely, S. aureus, Corynebacterium diphtheriae, 
Proteus vulgaris, Salmonella typhi, K. pneumoniae, 
and the fungal strain, Candida albicans. The bacterial 
and fungal cultures were swabbed in the MHA plates 
and 5 mm diameter wells were cut and about 40 µl of 
actinobacterial crude bioactive compounds (1 µg/1 µl) 
dissolved in 10% dimethyl sulfoxide (DMSO) was 
poured into each well of all the plates and then they 
were incubated at 37 °C for 24 h. After incubation, 
the zone of inhibition was measured12. 
 
Larvicidal activity  
For larvicidal activity, larvae of Culex 
quinquefasciatus (vectors of lymphatic filariasis) were 
acquired from the National Center for Disease Control 
Research Institute, Coonoor, India, and maintained in 
plastic trays containing dechlorinated tap water13. 
The larvae were exposed to a wide range of 
concentrations (PA9 extract) with control. A total of 25 
fourth-instar healthy larvae were transferred into a 
chamber with 250 ml tap water. Different concentrations 
(100, 300, 500, 700, and 900 µg/ml) of the actinobacterial 
solvent extract were added to 250 ml water to obtain the 
desired target dosage. Larval mortality was observed at 48 
h and larvae mortality percentage was calculated using the 
formula with triplicate larvicidal data14.  
Mortality (%) =X − Y/X × 100, where X = survival 
in the untreated control, Y = survival in the treated 
sample. 
 
Antioxidant activity 
DPPH radical scavenging activity: DPPH (1,1-
Diphenyl-2-picrylhydrazyl) was dissolved in 3.3 ml of 
methanol contained in test tubes.  The test tubes were 
covered with aluminium foil to protect them from 
light. Then about 150 µl of DPPH solution was added 
to 3 ml of methanol and the absorbance was recorded 
immediately at 517 nm for control reading. About 
100, 200, 300, 400, and 500 µl concentration of 
actinobacterial solvent fractions (stock concentration, 
i.e., 1 mg/1 ml), as well as the standard compound 
(ascorbic acid), were taken. Then added 3 ml of 
methanol and 150 µl of DPPH into all the reaction 
tubes. Absorbance was taken after 15 min at 517 nm 
using methanol as blank on the UV–Vis spectrometer, 
Cyber lab Model15. The DPPH free radical scavenging 
activity was calculated using the formula:  
 
Scavenging percentage = (T0 – T)/T0 × 100,  
 
where T0 = absorbance of control, T = absorbance of 
the test sample at 517 nm. 
Nitric oxide (NO) free radical scavenging activity: 
Different concentration (100, 200, 300, 400, and 500 µl) 
of the actinobacterial crude extract (1 mg/1 ml) 
dissolved in DMSO as well as ascorbic acid 
(standard) were taken in separate tubes; in each tube, 
2.0 ml of sodium nitroprusside in phosphate buffer 
saline was added. The solution was incubated at room 
temperature for 150 min. After incubation, 5 ml of 
Griess reagent was added in each tube, including the 
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control. Methanol was used as a blank. The 
absorbance was measured at 546 nm on the UV–Vis 
spectrometer15. The NO free radical scavenging 
activity was calculated using the formula:  
 
Scavenging percentage = (T0 – T)/T0 × 100 
 where T0 = absorbance of control, T = absorbance of 
the test sample at 546 nm. 
 
Fourier transform infrared (FTIR) spectral analysis 
The infrared (IR) spectrum of the compound PA9 
was determined by EXI-Spectrum FTIR Model. The 
spectrum was obtained using potassium bromide 
(KBr) pellets in the range of 4000 to 400 cm−1 at a 
resolution of 1.0 cm−1. Before the analysis, potassium 
bromide (AR grade) was dried under vacuum at 100 °C 
and 100 mg of KBr with 1 mg of sample was used to 
prepare KBr pellets. The spectrum was plotted as 
intensity versus wave number16. 
 
High-performance liquid chromatography (HPLC) 
analysis 
The metabolite profile of the actinobacterial extract 
was determined using analytical HPLC (Shimadzu, 
Japan). The chromatographic separation of the 
actinobacterial extract was carried out by LC-10 AT VP 
model HPLC using 15 cm × 4.6 mm CLC-ODS column 
(C-18). The mobile phase consisted of methanol (HPLC 
grade) and water (HPLC grade) at 9:1 ratio. The UV–
Vis (SPD-10 AVP) detector was set at 254 nm with 1 
ml/min flow rate. The sample was mixed with the 
solvent in the ratio of 50:50 and filtered using a 
Millipore filter. About 20 µL of the sample filtrate was 
injected into the column. The sample was allowed to run 
for 10 min and the crude compounds present in the 
extract of strain PA9 were identified on the basis of 
retention time and quantified17. 
 
Gas chromatography–mass spectrometry (GC–MS) 
analysis 
The GC–MS analysis of actinobacterial extract was 
done using BRUKER GC - Trace Ultra Ver: 6.0, 
Thermo MS dsq II, fitted with a silica capillary 
column (ZB5 - ms capillary standard nonpolar column 
– 30 × 0.25 mm I.D., Film thickness 0.25 μm). 
Hundred microliters of actinobacterial extract was 
injected into the chromatographic column. The 
process temperature was maintained at 70-260 °C at a 
rate of 6 °C/min for 2 min. The scan ranged from 50 
to 650 m/z. Compounds were identified based on 
comparison of their mass spectra with those of Wiley 
and NIST libraries18. 
Statistical analysis 
All the experiments were carried out in triplicate 
and subjected to statistical analysis carried out by 
variance value calculated using SPSS v.16 software. 
Results with P < 0.05 were measured to be 
statistically significant19. 
 
Results and Discussion 
During primary screening of the agar plug method, 
the strain PA9 showed maximum antibacterial activity 
on S. aureus (14 mm) and E. coli (16 mm) (Fig. 1). 
Furthermore, crude bioactive compounds from the 
strains PA9, PA12, PA6, and PA13 were extracted by 
agar-based solid-state fermentation using ethyl acetate 
as the solvent system. The available literature shows 
that agar-supported surface fermentation has 
comprehensive interest in the field of microbial 
secondary metabolites production due to notable 
advantages in the extraction and concentration of 
highly diluted compounds20. In the present study, 
secondary screening using crude extracts showed that 
the PA9 extract had maximum inhibition against test 
bacterial pathogen S. typhi (21.6 ± 0.88 mm) and 
fungal pathogen C. albicans (26.6 ± 0.88 mm) (Fig. 2 
and Table 1). Duddu and Guntuku21 have reported in 
vitro antimicrobial activity of actinomycetes (strain 
M3) isolated from the mangrove ecosystem which 
 
Fig. 1 — Antagonistic activity by the agar plug method (1-PA9, 
2-PA2, 3-PA8, 4-PA12, 5-PA7, 6-PA6, and 7-PA 13) 
 
 
 
Fig. 2 — Antibacterial study: zone of inhibition by clinical 
pathogens against actinobacterial solvent extract 
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showed maximum zone of inhibition on S. aureus 
(19.5 mm) and C. albicans (22.6 mm). Streptomyces 
parvus bioactive compounds were active against 
pathogenic bacteria; the maximum inhibition was 
recorded on P. aeruginosa (20 mm) and E. coli (20 
mm)22. Zothanpuia et al.23 have reported that 
Streptomyces cyaneofuscatus strain produced broad 
spectrum antimicrobial activities against bacterial and 
fungal pathogens. The maximum zone inhibition was 
obtained from E. coli MTCC 739 (15 mm) and  
C. albicans MTCC 3017 (12.6 mm). In the current 
study, the PA9 ethyl acetate extract showed promising 
activity against clinical pathogens and it was further 
used for larvicidal and antioxidant activity.  
The larvicidal effect of ethyl acetate extract of 
actinobacterial strain PA9 showed maximum larval 
mortality rate on C. quinquefasciatus (LC50=173.21 
µg/ml and r2=0.841) (Fig. 3 and Table 2). Similarly, 
the strain KA13 showed 100% mortality at 1000 ppm 
concentration and the strain KA25-A showed a 
maximum of 90% mortality at 24 h incubation24. 
Vijayakumar et al.25 have reported the larvicidal 
activity of Streptomyces sp. crude extract against C. 
quinquefasciatus as LC50=255.12 mg/L. Ganesan et 
al.26 reported that crude extracts of secondary 
metabolites of the actinomycete showed larvicidal 
activity against C. quinquefasciatus with  
LC50=170.55 mg/l. 
In the present study, significant scavenging activity 
was recorded (72% to 85%) using 1,1-Diphenyl-2-
picrylhydrazyl (DPPH) and NO free radical 
scavenging assay, respectively (Fig. 3). Priya et al.27 
have reported that the ethyl acetate extract of 
Streptomyces showed 83% of scavenging activity on 
DPPH assay. Vanmathi et al.28 isolated antioxidant 
compound from marine actinobacterium, which 
showed the maximum percentage of scavenging 
(40.24%) during NO radical scavenging assay. 
Similarly in the present study, PA9 extract also 
exhibited good scavenging of DPPH and NO free 
radical and it was near that of the standard. In an 
earlier investigation, antioxidant potential of ethyl 
acetate solvent extract from Streptomyces sp. 
VITMK1 was studied using DPPH radical and NO 
radical assay and the compound of VITMK1 strain 
showed strong DPPH radical scavenging activity 
(72.48 ± 0.32% at 500 μg/ml) and NO radical 
scavenging activity (73.03 ± 1.02% at 500 μg/ml)29.  
The results of FTIR spectroscopic analyses of PA9 
crude extract from the present study are given in 
Figure 4 and Table 3, which shows the presence of 
various functional groups of bioactive metabolites in 
the form of peaks. The results confirmed the presence 
of alcohol with a peak ratio at 3769.15 and 1183.48 
cm−1 which corresponded to O-H and C-O stretching 
frequency, respectively. The peak at 3429.11 and 
2078.37 cm−1 assigned to the –C=C- and -C-H- 
stretching indicates the presence of some alkyne 
compounds. The peak at 2926.62 and 1454.88 cm−1 
confirms alkane and the peak at 1655.94 cm−1 
confirms alkene. The FTIR functional groups were 
Table 1 — Antimicrobial activity of the actinobacterial extracts 
against clinically important pathogens.  
The results are presented as mean ± (SD) (n = 3) 
S. 
No
Bacterial and fungal 
Isolates 
Zone of inhibition (in mm) 
PA9 PA12 PA6 PA13 
 
1 
Bacteria 
Staphylococcus aureus 
15 ± 
0.57 
– 8.6 ± 
0.88 
– 
2 Cornybacterium 
diptheriae 
15.6 ± 
0.66 
– – 7.3 ± 
0.88 
3 Klebsiella pneumoniae 12.6 ± 
1.20 
– – – 
4 Proteus vulgaris 14.3 ± 
0.88 
– 8.3 ± 
1.85 
– 
5 Salmonella typhi 21.6 ± 
0.88 
– – – 
 Fungi     
6 Candida albicans 26.6 ± 
0.88 
– – – 
 
 
Fig. 3 — (a), Larvicidal activity of the actinobacterial extract 
against Culex quinquefasciatus. (b) and (c), DPPH and nitric 
oxide scavenging activity of PA9 extract 
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easily identified through standard IR functional data 
report. FTIR spectrum of ethyl acetate extract of AS9 
showed absorption at 3380 cm−1 peak, which indicates 
the N-H amino group, 2510 cm−1, 1798 cm−1, and 
1618 cm−1 peaks indicate C=C alkene group,  
1423 cm−1 indicates C=C aromatic group, 1140 cm−1 
peak indicates CF fluorine group, 998 cm−1, 874 cm−1, 
711 cm−1, 675 cm−1 peaks confirm C-CI, 656 cm−1 
peak shows C-CI, and 599 cm−1 peak confirms 
CBr-bromine group30. 
Faja et al.31 subjected crude compounds from 
potential actinobacterium to HPLC (HPLC-SPD-
20AShimadzu-Japan). Major peak value was recorded 
in the retention time of 5.36 min. In the present study, 
the crude extract of PA9 isolate showed many peaks 
in HPLC graph, with retention times (Fig. 5). Further 
purification and structure elucidation of bioactive 
compound is under progress.  
Different compounds such as 1-butene, 3-methyl- 
3-(methoxy ethoxy), pyrrolidine,1-(1-oxo- 
2, 5-octadecadienoyl), 3,4-dichlorophenethylamine, 3-
trifluoroacetoxypentadecane, octaethylene glycol mono 
dodecyl ether, 3-(Prop-2-enoyloxy) dodecane, 
1,4,7,10,13,16-hexaoxacyclo-octadecane, heptaethylene 
glycol, and ethanol, 2-[2-(2-ethoxyethoxy) ethoxy] were 
present in the sample (Fig. 6  and Tables 4 and 5). The 
GC–MS characterization of actinobacteria SMS_SU21 
showed the presence of four major compounds, 
vinylbital, 2,6-triazolo[1,5-a] pyrimidine, 5,7-dimethyl1-
2-phenyl, and digitoxigenin. All the major compounds 
Table 2 — Larvicidal activity of the actinobacterial (PA9) extract against Culex quinquefasciatus 
Sample  Concentra 
tions (mg/l) 
*Percent 
mortality ± SD 
LC50 (µg/ml) 
(LCL–UCL) 
r2 Regression equation
PA9 extract  
 
100 40 ± 0.57  
 
173.21 (80.91-370.78) 
 
 
0.841 
 
 
Y = 0.056X+41.6 
300 60 ± 1.0 
500 80 ± 1.15 
700 84 ± 1.52 
900 84 ± 1.52 
Control (DMSO) 900 – 
*Significant at P˂0.05 level, LC50 lethal concentration that kills 50 % of the exposed larvae, UCL upper confidence limit, 
LCL lower confidence limit, r2 regression 
 
Table 3 — FTIR peaks and their respective assigned functional groups (PA9) 
S.NO FTIR peak (cm−1) Stretching and bending vibration Assigned functional group 
1 3769.15 O–H (Stretch) Hydroxyl (or) Alcohol 
2 3429.11 –C–H– (Stretch) Alkyne 
3 2926.62 C–H (Stretch) Alkane 
4 2078.37 –C=C– (Stretch) Alkyne 
5 1655.94 C=C (Stretch) Alkene 
6 1454.88 –C–H– (Bending) Alkane 
7 1183.48 C–O (Stretch) Alcohol 
 
 
Fig. 5 — HPLC chromatogram of potent bioactive crude 
compound 
 
Fig. 4 — FTIR analysis of ethyl acetate extract of potential
strain PA9 
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are related to antimicrobial, antioxidant, and cytotoxic 
properties32. Khattab et al.33 have reported that GC–MS 
analysis of Streptomyces exhibited eight compounds 
gained from the PS 1 isolate and 11 compounds 
gained from the PS 28 isolate. The crude compound 
of the isolate TS 1010 was characterized by GC–MS. 
The GC–MS showed a list of 13 bioactive molecules 
and among them three were found to have 
antimicrobial, anticancer, and antibacterial 
activities34. 
 
Conclusion 
In the present study, an actinobacteria, 
Streptomyces sp (PA9) was isolated from mangrove 
soil and screened for its ability to produce bioactive 
compounds against antimicrobial, larvicidal, and 
antioxidant activity. Further, the compound was 
characterized by FTIR, HPLC, and GC–MS. The 
extracted bioactive compound has shown good 
antimicrobial, larvicidal, and antioxidant properties. 
Table 4 — The major components found during the GC–MS analysis of the ethyl acetate extract of Streptomyces PA9 
S. No RT Name of the compounds Mol. wt Mol. form 
1 5.39 1-Butene, 3-methyl-3-(1 ethoxyethoxy) 158 C9H18O2 
2 7.82 Pyrrolidine, 1-(1-oxo-2,5-octadecadienyl) 333 C22H39NO 
3 12.73 3,4-Dichlorophenethylamine 189 C8H9CL2N 
4 13.173 3-Trifluoroacetoxypentadecane 324 C17H31F3O2 
5 15.453 Octaethylene glycol monododecyl ether 538 C28H58O9 
6 17.530 3-(Prop-2-enoyloxy)dodecane 240 C15H28O2 
7 19.554 1,4,7,10,13,16-Hexaoxacyclooctadecane 264 C12H24O6 
8 20.947 Heptaethylene glycol 326 C14H30O8 
9 23.133 Ethanol, 2-[2-(2-ethoxyethoxy)ethoxy] 178 C8H18O4 
Table 5 — Properties of major components found in ethyl acetate extracts of Streptomyces PA9 
S.NO Name of the compounds Applications of the compounds 
1 1-Butene, 3-methyl-3-(1 ethoxyethoxy) Antibacterial activity 
2 Pyrrolidine, 1-(1-oxo-2,5-octadecadienyl) No activity reported  
 
3 3,4-Dichlorophenethylamine Cytotoxic activity 
Anticancer activity 
4 3-Trifluoroacetoxypentadecane Used as an nephro-protective 
Possesses antioxidant activities 
Antimicrobial activities 
5 Octaethylene glycol monododecyl ether No activity reported  
 
6 3-(Prop-2-enoyloxy)dodecane No activity reported  
 
7 1,4,7,10,13,16-Hexaoxacyclooctadecane Synthesis of 2-cyanoethyl-O-β-cholesterol ether 2 
8 Heptaethylene glycol Antioxidant activity 
Anticancer activity 
9 Ethanol, 2-[2-(2-ethoxyethoxy)ethoxy] No activity reported  
 
Fig. 6 — GC–MS analysis of metabolites synthesized by
actinobacterial strain PA9 
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Further research is in progress for compound 
identification, structure elucidation, and production of 
the bioactive compound in large quantities to make it 
industrially important. 
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